Pharmasimple SA operates a Website for medicines, cosmetics, and food supplements in Belgium and France. More Details
Moderate growth potential with mediocre balance sheet.
Share Price & News
How has Pharmasimple's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALPHS is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ALPHS's weekly volatility (4%) has been stable over the past year.
7 Day Return
FR Online Retail
1 Year Return
FR Online Retail
Return vs Industry: ALPHS underperformed the French Online Retail industry which returned 47.7% over the past year.
Return vs Market: ALPHS exceeded the French Market which returned 1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Pharmasimple's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StPharmasimple (EPA:ALPHS) Is Carrying A Fair Bit Of Debt
3 months ago | Simply Wall StAnalysts Are Optimistic We'll See A Profit From Pharmasimple SA (EPA:ALPHS)
6 months ago | Simply Wall StWhen Will Pharmasimple SA (EPA:ALPHS) Breakeven?
Is Pharmasimple undervalued compared to its fair value and its price relative to the market?
Share Price vs. Fair Value
Below Fair Value: ALPHS (€8.1) is trading above our estimate of fair value (€4.77)
Significantly Below Fair Value: ALPHS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: Insufficient data to calculate ALPHS's PE Ratio to determine if it is good value compared to the FR Online Retail industry average.
PE vs Market: Insufficient data to calculate ALPHS's PE Ratio to determine if it is good value compared to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALPHS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: Insufficient data to calculate ALPHS's PB Ratio to determine if it is good value.
How is Pharmasimple forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALPHS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Earnings vs Market: ALPHS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALPHS's is expected to become profitable in the next 3 years.
Revenue vs Market: ALPHS's revenue (1.7% per year) is forecast to grow slower than the French market (7.3% per year).
High Growth Revenue: ALPHS's revenue (1.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALPHS's Return on Equity is forecast to be high in 3 years time
How has Pharmasimple performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALPHS is currently unprofitable.
Growing Profit Margin: ALPHS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALPHS is unprofitable, and losses have increased over the past 5 years at a rate of 26.4% per year.
Accelerating Growth: Unable to compare ALPHS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALPHS is unprofitable, making it difficult to compare its past year earnings growth to the Online Retail industry (30.6%).
Return on Equity
High ROE: ALPHS has a negative Return on Equity (-20.61%), as it is currently unprofitable.
How is Pharmasimple's financial position?
Financial Position Analysis
Short Term Liabilities: ALPHS's short term assets (€15.1M) exceed its short term liabilities (€12.0M).
Long Term Liabilities: ALPHS's short term assets (€15.1M) exceed its long term liabilities (€5.4M).
Debt to Equity History and Analysis
Debt Level: ALPHS's debt to equity ratio (115.8%) is considered high.
Reducing Debt: ALPHS's debt to equity ratio has reduced from 125.1% to 115.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ALPHS has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALPHS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Pharmasimple current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALPHS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALPHS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALPHS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALPHS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALPHS's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Michaël Willems has been the Chief Executive Officer and Chairman of Pharmasimple SA since October 31, 2013.
|Chairman & CEO||7.17yrs||no data||no data|
|Director||5.42yrs||no data||no data|
|Director||3.25yrs||no data||no data|
Experienced Board: ALPHS's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 85.3%.
Pharmasimple SA's company bio, employee growth, exchange listings and data sources
- Name: Pharmasimple SA
- Ticker: ALPHS
- Exchange: ENXTPA
- Founded: 2010
- Industry: Internet and Direct Marketing Retail
- Sector: Retail
- Market Cap: €23.406m
- Shares outstanding: 2.89m
- Website: https://www.pharmasimple.com
Number of Employees
- Pharmasimple SA
- Millennium Boulevard 11
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALPHS||ENXTPA (Euronext Paris)||Yes||Bearer Shares||FR||EUR||Nov 2016|
Pharmasimple SA operates a Website for medicines, cosmetics, and food supplements in Belgium and France. It offers beauty and cosmetics products, such as face wash, face care, make-up, hair removal, body c...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/03 19:26|
|End of Day Share Price||2020/12/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.